Sort   by:  
 Page size 
TranscriptomicsEffect of deferasirox and deferoxamine treatment on hematopoietic stem cells gene expression
To investigate new molecular pathways affected by deferasirox or deferoxamine able to explain hematopoiesis restoration
ORGANISM(S): Homo sapiens 
2019-09-02 | E-MTAB-6658 | biostudies-arrayexpress
TranscriptomicsInvestigation of gene expression alterations of pancreatic cancer caused by Deferasirox administration
To investigate the genetic effect of Deferasirox in pancreatic cancer, we examined gene expression alternations in the removed tumors exposed to Deferasirox. Pancreatic cancer cells (BxPC-3) in culture were harvested and viable cells were injected subcutaneously into the backs of the mice. When tumo...
ORGANISM(S): Homo sapiens 
2016-05-13 | E-GEOD-81363 | biostudies-arrayexpress
ClinicalDeferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic malignancies.
2100588 | ecrin-mdr-crc
TranscriptomicsInvestigation of gene expression alterations of pancreatic cancer caused by Deferasirox administration
To investigate the genetic effect of Deferasirox in pancreatic cancer, we examined gene expression alternations in the removed tumors exposed to Deferasirox.
ORGANISM(S): Homo sapiens 
2016-05-13 | GSE81363 | GEO
GenomicsGene expression profiling in myelodysplastic syndrome patients treated with deferasirox
Gene expression profiling in myelodysplastic syndrome patients treated with deferasirox
PRJNA674306 | ENA
TranscriptomicsGenome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients
The iron chelator deferasirox is widely used in patients with iron overload. Patients with low-grade myelodysplastic syndromes (MDS) get transfusion dependency and need to be treated with deferasirox to avoid iron overload. Moreover, in some patients an increase in both erythroid and platelets have ...
ORGANISM(S): Homo sapiens 
2019-12-13 | GSE141958 | GEO
GenomicsGenome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients
Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients
PRJNA595388 | ENA
GenomicsIron Chelator Deferasirox Reduces Candida albicans Invasion of Oral Epithelial Cells and Infection Levels in Murine Oropharyngeal Candidiasis
Iron Chelator Deferasirox Reduces Candida albicans Invasion of Oral Epithelial Cells and Infection Levels in Murine Oropharyngeal Candidiasis
PRJNA508086 | ENA
ProteomicsOxidative stress in myelodysplastic syndromes
Control of oxidative stress in the bone marrow (BM) is key for maintaining the balance between self-renewal, proliferation, and differentiation of hematopoietic cells. Breakdown of this regulation can lead to diseases characterized by BM failure such as the myelodysplastic syndromes (MDS). To better...
ORGANISM(S): Homo sapiens (Human) 
2019-10-30 | PXD013609 | Pride
Carbonylation Deferasirox Oxidative stress Myelodysplastic syndromes 
UnknownDeferasirox pharmacokinetics in patients with adequate versus inadequate response.
Not available
S-EPMC2774541 | biostudies-literature
Sort   by:  
 Page size